Why Doctors Are Calling Daraxonrasib a Game-Changer for Pancreatic Cancer

Daraxonrasib, an experimental once daily oral drug developed by Revolution Medicines, is emerging as one of the biggest breakthroughs in pancreatic cancer treatment after delivering unprecedented results in a Phase 3 clinical trial. The drug nearly doubled median overall survival for patients with previously treated metastatic pancreatic cancer and significantly outperformed standard chemotherapy across multiple clinical endpoints.

The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine, received a standing ovation from cancer specialists. Experts say the results could change the standard treatment approach for patients with advanced pancreatic cancer, a disease long considered one of the most difficult cancers to treat.

Daraxonrasib Breakthrough at a Glance

Particulars	Details
Drug Name	Daraxonrasib
Developer	Revolution Medicines
Drug Type	Once daily oral KRAS inhibitor
Target Disease	Previously treated metastatic pancreatic cancer
FDA Status	Priority Review Accepted
Current Status	Experimental drug with Expanded Access Program

Why Daraxonrasib Is Considered a Major Breakthrough

Pancreatic cancer has historically been one of the deadliest forms of cancer, with limited treatment options after first line therapy stops working. More than 90% of pancreatic cancers are driven by mutations in the KRAS gene, which for decades was considered impossible to target with medicines.

Daraxonrasib changes that outlook by directly targeting mutated KRAS proteins that fuel cancer growth. According to the Phase 3 RASolute 302 trial, the drug delivered statistically significant improvements in overall survival, progression free survival, tumor response rates and patient quality of life compared with standard chemotherapy.

Key Clinical Benefits

Clinical Measure	Daraxonrasib	Chemotherapy
Median Overall Survival	13.2 Months	6.6 to 6.7 Months
Risk of Death	Reduced by 60%	Standard Treatment
Progression Free Survival	7.3 Months	3.5 Months
Overall Response Rate	33.2%	11.8%

Survival Nearly Doubled in the Phase 3 Trial

The most remarkable outcome from the study was the improvement in overall survival. Patients receiving daraxonrasib lived a median of 13.2 months, compared with approximately 6.7 months for those receiving standard chemotherapy. The treatment also reduced the risk of death by about 60%, making it one of the most significant advances reported in pancreatic cancer treatment in recent years.

The benefit extended beyond survival alone. At the 12 month mark, 53.3% of patients receiving daraxonrasib were still alive, compared with only 18.7% of patients treated with chemotherapy.

Survival Outcomes

Measure	Daraxonrasib	Chemotherapy
Median Overall Survival	13.2 Months	6.7 Months
Twelve Month Survival Rate	53.3%	18.7%
Risk of Death	60% Lower	Baseline

Better Quality of Life and Fewer Serious Side Effects

Along with improving survival, daraxonrasib also demonstrated better tolerability than chemotherapy. Although most patients experienced treatment related side effects, significantly fewer patients receiving daraxonrasib required dose reductions or discontinued treatment because of adverse events.

Patients also experienced a longer period before pain worsened and maintained a better overall quality of life. These findings are particularly important because many patients with advanced pancreatic cancer struggle with severe symptoms that affect daily living.

Safety and Quality of Life

Measure	Daraxonrasib	Chemotherapy
Dose Reductions Due to Side Effects	36.1%	57.5%
Serious Side Effects	10.8%	18.7%
Time Before Significant Pain Increase	9.2 Months	3.8 Months
Positive Quality of Life	5.7 Months	2.6 Months

FDA Priority Review Brings the Drug Closer to Patients

Following the strong Phase 3 results, the US Food and Drug Administration accepted the company's New Drug Application under its Priority Review process. This designation is granted to medicines that could provide significant improvements over existing treatments and generally shortens the regulatory review timeline.

While the medicine has not yet received full FDA approval, eligible patients with serious or life threatening pancreatic cancer may already be able to receive daraxonrasib through the FDA Expanded Access Program if they have exhausted available treatment options and meet eligibility requirements.

Regulatory Status

Category	Status
FDA Review	Priority Review
Clinical Trial Stage	Phase 3 Completed
FDA Approval	Pending
Expanded Access	Available for Eligible Patients

What This Means for Pancreatic Cancer Treatment

Doctors believe daraxonrasib could become a new standard treatment for patients with previously treated metastatic pancreatic cancer if regulatory approval is granted. Researchers are also studying the drug as a potential first line treatment, which could further improve outcomes for future patients.

Although daraxonrasib is not a cure, the combination of longer survival, improved quality of life, better tolerability and strong clinical trial results represents one of the most promising developments in pancreatic cancer research in decades. Continued regulatory progress and additional clinical studies will determine how broadly the medicine can be used in the future.

Key Monitorables

Factor	Why It Matters
FDA Priority Review	Potential Approval Timeline
First Line Clinical Trials	Broader Treatment Use
Long Term Survival Data	Clinical Benefit
Expanded Access Program	Patient Availability
Regulatory Decision	Commercial Launch

What is daraxonrasib?

Daraxonrasib is an experimental once daily oral KRAS inhibitor developed by Revolution Medicines. It is designed to target mutated KRAS proteins, which drive more than 90% of pancreatic cancer cases.

Why is daraxonrasib being called a game changer for pancreatic cancer?

Doctors consider daraxonrasib a major breakthrough because it nearly doubled median overall survival, significantly reduced the risk of death by about 60%, improved progression free survival and offered a better quality of life compared with standard chemotherapy in a Phase 3 clinical trial.

How much did daraxonrasib improve survival in the Phase 3 trial?

Patients treated with daraxonrasib had a median overall survival of 13.2 months, compared with 6.6 to 6.7 months for those receiving standard chemotherapy.

How effective was daraxonrasib at reducing the risk of death?

In patients with RAS G12 mutations, daraxonrasib reduced the risk of death by approximately 60% compared with standard chemotherapy, making it one of the most promising advances in pancreatic cancer treatment.

Is daraxonrasib approved by the US FDA?

Not yet. The US Food and Drug Administration has accepted the drug's New Drug Application for Priority Review, which means the regulatory review process is being expedited because the treatment could provide significant clinical benefits.

Can patients access daraxonrasib before FDA approval?

Yes. Eligible patients with serious or life threatening metastatic pancreatic cancer may be able to receive daraxonrasib through the FDA Expanded Access Program if they have exhausted available treatment options and meet the required eligibility criteria.

What side effects were reported with daraxonrasib?

The most common side effects included rash, oral swelling and mouth sores. However, the drug was generally better tolerated than standard chemotherapy, with fewer patients requiring dose reductions or experiencing serious treatment related side effects.

Is daraxonrasib a cure for pancreatic cancer?

No. Daraxonrasib is not a cure for pancreatic cancer. However, clinical trial results show that it can significantly improve survival, delay disease progression and enhance quality of life for patients with previously treated metastatic pancreatic cancer, making it one of the most promising new treatment options under development.